New Blood Test May Predict Alzheimer's Risk
Recent studies suggest that a blood test could help determine the likelihood of seemingly healthy older adults developing Alzheimer's symptoms within a span of five to ten years. While this information could be either comforting or frightening, it's currently being viewed as a method to accelerate drug development. This is achieved by identifying individuals at high risk and including them in studies related to potential Alzheimer's treatments or prevention strategies.
A Tool to Expedite Drug Trials
Large-scale clinical trials are currently underway to determine if certain drugs could prevent or at least delay Alzheimer's. If any of these drugs prove to be effective, physicians would require a simple method to identify potential candidates for trying these treatments. However, the scientists who conducted these studies have warned that it's still too early for healthy individuals to seek out the p-tau217 test, which is used to help diagnose whether people with cognitive issues have Alzheimer's or a different disorder.
Know When to Get Tested
Experts suggest waiting to get tested until there's something that can potentially be done about the condition. Lifestyle changes such as a healthy diet, adequate sleep, regular exercise, and staying mentally active are still recommended for overall good health.
Findings from the Study
The study revealed that symptom-free older adults with very high levels of p-tau217 had a 38% risk of developing cognitive impairment over five years and a 78% risk over ten years. Although the exact cause of Alzheimer's is still unknown, its characteristic signs are brain-blocking amyloid plaques and neuron-killing tau tangles. The p-tau217 test measures a form of tau that correlates with the amount of plaque buildup and provides a clue about tau tangles.
Data Analysis and Results
The research team analyzed data from 2,684 older adults who were healthy at the time of joining the Alzheimer's studies. These individuals received the p-tau217 blood test upon enrollment and underwent yearly cognitive checkups. Approximately 478 of these participants developed cognitive impairment between the earliest enrollment and last year. It was observed that participants with very low p-tau217 levels also had a low risk of developing cognitive impairment over the five to ten-year period.
Amyloid Plaques and Tau Tangles
There's a dilemma in predicting Alzheimer's: many people have high levels of amyloid plaques but never develop dementia. A popular theory suggests that at some point, amyloid buildup triggers an abnormal type of tau to form tangles, leading to symptoms. The blood test data provides some new insights. While different intermediate levels of p-tau217 signaled progressive risk, only the very highest level appeared to correlate with other evidence about this tipping point.
A Word of Caution
Though the study has been praised by scientists not involved in it, they've also suggested reasons to be cautious. One reason is that only a small fraction of study participants were tracked for a full ten years, meaning there's less confidence in the ten-year risk estimate compared to the five-year risk estimate. Additionally, the predictions could be influenced by other factors. Older individuals may be at risk of dying from another cause, or they could have heart-related problems that can cause vascular dementia rather than Alzheimer's.
The Future of Alzheimer's Testing
Despite these cautions, the blood tests have shown significant potential. There are already individuals seeking this blood test, particularly those with a family history of Alzheimer's. However, experts discourage this for now. The predictive power of the blood test would be incredibly valuable, but only if ongoing studies eventually find a drug that could assist people before symptoms begin.
Recent studies suggest that a blood test could help determine the likelihood of seemingly healthy older adults developing Alzheimer's symptoms within a span of five to ten years. While this information could be either comforting or frightening, it's currently being viewed as a method to accelerate drug development. This is achieved by identifying individuals at high risk and including them in studies related to potential Alzheimer's treatments or prevention strategies.
A Tool to Expedite Drug Trials
Large-scale clinical trials are currently underway to determine if certain drugs could prevent or at least delay Alzheimer's. If any of these drugs prove to be effective, physicians would require a simple method to identify potential candidates for trying these treatments. However, the scientists who conducted these studies have warned that it's still too early for healthy individuals to seek out the p-tau217 test, which is used to help diagnose whether people with cognitive issues have Alzheimer's or a different disorder.
Know When to Get Tested
Experts suggest waiting to get tested until there's something that can potentially be done about the condition. Lifestyle changes such as a healthy diet, adequate sleep, regular exercise, and staying mentally active are still recommended for overall good health.
Findings from the Study
The study revealed that symptom-free older adults with very high levels of p-tau217 had a 38% risk of developing cognitive impairment over five years and a 78% risk over ten years. Although the exact cause of Alzheimer's is still unknown, its characteristic signs are brain-blocking amyloid plaques and neuron-killing tau tangles. The p-tau217 test measures a form of tau that correlates with the amount of plaque buildup and provides a clue about tau tangles.
Data Analysis and Results
The research team analyzed data from 2,684 older adults who were healthy at the time of joining the Alzheimer's studies. These individuals received the p-tau217 blood test upon enrollment and underwent yearly cognitive checkups. Approximately 478 of these participants developed cognitive impairment between the earliest enrollment and last year. It was observed that participants with very low p-tau217 levels also had a low risk of developing cognitive impairment over the five to ten-year period.
Amyloid Plaques and Tau Tangles
There's a dilemma in predicting Alzheimer's: many people have high levels of amyloid plaques but never develop dementia. A popular theory suggests that at some point, amyloid buildup triggers an abnormal type of tau to form tangles, leading to symptoms. The blood test data provides some new insights. While different intermediate levels of p-tau217 signaled progressive risk, only the very highest level appeared to correlate with other evidence about this tipping point.
A Word of Caution
Though the study has been praised by scientists not involved in it, they've also suggested reasons to be cautious. One reason is that only a small fraction of study participants were tracked for a full ten years, meaning there's less confidence in the ten-year risk estimate compared to the five-year risk estimate. Additionally, the predictions could be influenced by other factors. Older individuals may be at risk of dying from another cause, or they could have heart-related problems that can cause vascular dementia rather than Alzheimer's.
The Future of Alzheimer's Testing
Despite these cautions, the blood tests have shown significant potential. There are already individuals seeking this blood test, particularly those with a family history of Alzheimer's. However, experts discourage this for now. The predictive power of the blood test would be incredibly valuable, but only if ongoing studies eventually find a drug that could assist people before symptoms begin.